<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, shrink-to-fit=no">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Finerenone - Ensayos clínicos de fase 3; FIGARO-DKD, FIDELIO-DKD y FIDELITY</title>
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
  <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
  <link rel="stylesheet" href="assets/css/styles.css">
  <link rel="stylesheet" href="assets/fonts/fontawesome-all.min.css">
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.0/jquery.min.js"></script>
  <script src="assets/js/javascript.js"></script>
</head>

<body>
  <div class="row">
   <h3 style="font-size: 28px; width: 100%; color: white; font-weight: bold; background: #00617f; padding-top: 10px; padding-bottom: 10px;padding-left: 25px;">Finerenone - Ensayos clínicos de fase 3; FIGARO-DKD, FIDELIO-DKD y FIDELITY
    </h3>
  </div>

  <div class="card">
    <ul class="nav nav-tabs" role="tablist">
      <li class="nav-item" role="presentation">
        <a class="nav-link active" id="summary_tab" role="tab" data-bs-toggle="tab" data-bs-target="#summary" href="#summary" role="tab" aria-controls="summary" aria-selected="true">
          Resumen
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="FIDELIO-DKD_tab" role="tab" data-bs-toggle="tab" data-bs-target="#FIDELIO-DKD" href="#FIDELIO-DKD" role="tab">
          Phase 3 - FIDELIO-DKD
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="FIGARO-DKD_tab" role="tab" data-bs-toggle="tab" href="#FIGARO-DKD">
          Phase 3 - FIGARO-DKD
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id="pooled_analysis_tab" role="tab" data-bs-toggle="tab" href="#pooled_analysis-fidelity">
          Pooled analysis - FIDELITY
        </a>
      </li>
      <li class="nav-item" role="presentation">
        <a class="nav-link" id ="references_tab" role="tab" data-bs-toggle="tab" href="#references">
          References
        </a>
      </li>
    </ul>
  </div>
          
  <div class="tab-content">
    <div id="summary" class="tab-pane show active" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Resumen
        </h1>
        <p style="font-size: 18px; margin-left: 35px">
          <em>Por favor, consulte la ficha técnica aprobada de finerenona para obtener más información sobre el producto.*</em>
        </p>
        <ul class="bullet">
          <li>
            En los estudios pivotales (de registro) del programa de desarrollo clínico de finerenona, se han comunicado los datos sobre el efecto de finerenona en pacientes con enfermedad renal crónica (CKD) y diabetes tipo 2 (T2D), o CKD e insuficiencia cardíaca (HF).
          </li>
          <li>
            Una vez completados con éxito los estudios de fase 2: ARTS, ARTS-DN y ARTS-HF,<sup>1-3</sup> se inició el programa de fase 3 de finerenona, formado por dos estudios complementarios de fase 3, multicéntricos, aleatorizados, doble ciego, controlados con placebo y basados en eventos: los estudios <a id="link" onclick="link2()">FIDELIO-DKD</a> y <a id="link" onclick="link3()">FIGARO-DKD</a>; así como un análisis conjunto de ambos ensayos: <a id="link" onclick="link4()">FIDELITY</a>.<sup>4-7</sup>
          </li>
          <li>
            En el estudio <a id="link" onclick="link2()">FIDELIO-DKD</a> se investigó principalmente la eficacia y la seguridad de finerenona para retrasar la progresión de la CKD. La incidencia del criterio de valoración principal compuesto (insuficiencia renal, disminución sostenida de &ge;40% de la tasa de filtración glomerular estimada [eGFR] con respecto al valor inicial, o muerte por causas renales) fue significativamente menor en el grupo de finerenona que en el de placebo, ocurriendo en 504 pacientes (17.8%) y 600 pacientes (21.1%), respectivamente (Hazard Ratio [HR], 0.82; intervalo de confianza [CI] del 95%, 0.73-0.93; P = 0.001). La incidencia de eventos adversos emergentes del tratamiento (TEAE) en los grupos de finerenona frente a placebo fue del 87.3% y el 87.5%, respectivamente. Se produjeron eventos adversos graves (SAE) emergentes del tratamiento en el 31.9% y el 34.3% de los pacientes de los grupos de finerenona y placebo, respectivamente.<sup>4,5</sup>
          </li>
          <li>
            <a id="link" onclick="link3()">FIGARO-DKD</a> evaluó la eficacia y la seguridad de finerenona en la reducción de la morbilidad y la mortalidad cardiovascular (CV). El resultado del criterio de valoración principal compuesto (incidencia de muerte CV, infarto de miocardio [MI] no mortal, ictus no mortal u hospitalización por insuficiencia cardiaca [HHF]) fue significativamente inferior en el grupo de finerenona que en el de placebo (458/3686 pacientes [12.4%] frente a 519/3666 pacientes [14.2%]; HR, 0.87; CI del 95%, 0.76 a 0.98; P = 0.03). Este efecto fue consistente en todos los subgrupos preespecificados.<sup>4-6</sup> En general, el 85.1% de los pacientes en el grupo de finerenona y el 85.5% de los pacientes en el grupo de placebo experimentaron un acontecimiento adverso (AE). De estos, el 31.4% y el 33.2% fueron SAE en el grupo de finerenona y en el de placebo, respectivamente.<sup>6</sup>
          </li>
          <li>
            <a id="link" onclick="link4()">FIDELITY</a> es un estudio agrupado de ambos ensayos diseñado para proporcionar estimaciones más robustas de la eficacia y seguridad del análisis de finerenona frente a placebo en un amplio espectro de CKD. Después de una mediana de seguimiento de 3.0 años, el criterio de valoración CV compuesto se observó en 825 (12.7%) pacientes que recibieron finerenona y 939 (14.4%) que recibieron placebo (HR, 0.86; 95% CI, 0.78-0.95; P = 0.0018). El criterio de valoración renal compuesto se observó en 360 (5.5%) pacientes que recibieron finerenona y 465 (7.1%) que recibieron placebo (HR, 0.77; CI del 95%, 0.67-0.88; P = 0.0002). En general, los criterios de seguridad fueron similares entre los distintos grupos de tratamiento; sin embargo, la hiperpotasemia que obligó a interrumpir definitivamente el tratamiento fue más frecuente en los pacientes que recibieron finerenona (1.7%) que en los que recibieron placebo (0.6%).<sup>7</sup>
          </li>
        </ul>

        <p style="font-size: 17px; margin-left: 35px">
          <em>*Compruebe la disponibilidad local de finerenona en su región.</em>
        </p>
      </div><br><br>
    </div>

    <div id="FIDELIO-DKD" class="tab-pane" role="tabpanel">
      <div class="container-fluid">
        <h1>
          Phase 3 - FIDELIO-DKD
        </h1>
        <div class="accordion">
          <div class="accordion-item">
            <h2 class="accordion-header" id="heading 1">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-1">
                Trial Design
              </button>
            </h2>
            <div id="collapse-1" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  In FIDELIO-DKD, <strong>Bakris et al (2020)<sup>4</sup></strong> investigated the efficacy and safety of finerenone in delaying CKD progression with CV morbidity and mortality being secondary endpoints in patients with advanced CKD and T2D when used in addition to standard of care.
                </p>
              </div>
            </div>
          </div>
              
          <div class="accordion-item">
            <h2 class="accordion-header" id="patients">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-2">
                Patients
              </button>
            </h2>
            <div id="collapse-2" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  Following screening, a total of 5734 patients with an eGFR ≥25 to <75 mL/min/1.73 m<sup>2</sup> and albuminuria (UACR ≥30 to ≤5000 mg/g) were randomized 1:1 to receive finerenone (10 or 20 mg OD) or placebo. Patients with an eGFR at the screening visit of 25 and up to 60 mL/min/1.73 m<sup>2</sup> received an initial dose of 10 mg OD, and those with an eGFR of at least 60 mL/min/1.73 m<sup>2</sup> received an initial dose of 20 mg OD. All patients were also treated with an ACEI or ARB at the manufacturer's maximum tolerated dose. At screening patients were required to have a serum potassium level of ≤4.8 mmol/l. Following 1 month of treatment, the finerenone dose was increased from 10 mg OD to 20 mg OD provided the serum potassium levels remained below 4.8 mmol/l and eGFR was stable.<sup>4</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="results">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-3">
                Results
              </button>
            </h2>
            <div id="collapse-3" class="accordion-collapse collapse">
              <div class="accordion-body">
                <p class="collapse-text">
                  The mean age at baseline was 65.4 ± 8.9 (years) in the finerenone group (N=2833) and 65.7 ± 9.2 in the placebo group (N=2841) and following trial completion there was a median follow-up time of 2.6 years.<sup>4</sup>
                </p>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="efficacy outcomes">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-4">
                Efficacy Outcomes
              </button>
            </h2>
            <div id="collapse-4" class="accordion-collapse collapse">
              <div class="accordion-body">
                <ul class="bullet-collapse">        
                  <li>
                    The incidence of the primary composite outcome (kidney failure, sustained ≥40% decrease in eGFR from baseline, or renal death) was significantly lower in the finerenone group than in the placebo group, occurring in 504 patients (17.8%) and 600 patients (21.1%), respectively (HR, 0.82; 95% CI, 0.73-0.93; P = 0.001).This effect was also consistent across prespecified subgroups.<sup>4</sup>
                  </li>
                  <li>
                    Based on an ARR of 3.4% (95% CI, 0.6-6.2%) after 3 years, the NNT to prevent one primary outcome event was 29 (95% CI, 16-166).<sup>4</sup>
                  </li>
                  <li>
                    The key secondary composite outcome, assessed in a time-to-event analysis, (composite of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or HHF) occurred in 367 (13%) and 420 (14.8%) patients in the finerenone and placebo groups, respectively (HR, 0.86; 95% CI, 0.75-0.99; P = 0.03).<sup>4</sup>
                  </li>
                  <li>
                    Based on an ARR of 2.4% (95% CI, 0.3-4.5%) after 3 years, the NNT to prevent a secondary event was 42 (95% CI, 22-397).<sup>4</sup>
                  </li>
                </ul>
              </div>
            </div>
          </div>

          <div class="accordion-item">
            <h2 class="accordion-header" id="safety outcomes">
              <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-5">
                Safety Outcomes
              </button>
            </h2>
            <div id="collapse-5" class="accordion-collapse collapse">
              <div class="accordion-body">
                <ul class="bullet-collapse">        
                  <li>
                    The incidence of TEAEs in the finerenone vs. placebo groups was 87.3% and 87.5%, respectively. Treatment-emergent SAEs occurred in 31.9% and 34.3% of patients in the finerenone and placebo groups, respectively.
                  </li>
                  <li>
                    The most common TEAE in finerenone-treated patients was hyperkalemia; hyperkalemia-related AEs were observed in 18.3% and 9.0% of patients in the finerenone arm and placebo arm, respectively. Hypokalemia occurred in 1.0% of finerenone treated patients and 2.2% of patients who received placebo.
                  </li>
                  <li>
                    Changes in mean SBP from baseline of -3.0 (month 1) and -2.1 mmHg (month 12) - were seen with finerenone and of- 0.1 and 0.9 mmHg with placebo, respectively
                  </li>
                  <li>
                    Maximal difference of mean change in HbA1c from baseline was observed at month 36 (0.16% for finerenone vs 0.07% for placebo).
                  </li>
                  <li>
                    Patients treated with finerenone had a higher mean serum potassium than those treated with placebo, with a maximal difference of 0.23 mEq/L observed at month 4. The incidences of serum potassium levels of more than 5.5 mmol per liter and more than 6.0 mmol per liter were 21.7% and 4.5%, respectively, in the finerenone group and 9.8% and 1.4%, respectively, in the placebo group.
                  </li>
                </ul>
              </div>
            </div>
          </div>   
        </div><br></div><br><br><br>
      </div>
            
      <div id="FIGARO-DKD" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            Phase 3 - FIGARO-DKD
          </h1>
          <div class="accordion">
            <div class="accordion-item">
              <h2 class="accordion-header" id="heading 6">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-6">
                  Trial Design
                </button>
              </h2>
              <div id="collapse-6" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    In FIGARO -DKD, <strong>Pitt et al (2021)<sup>6</sup></strong> evaluated whether finerenone treatment would lower the risk of CV events and CV death among patients with either stage 2 to 4 CKD and moderately elevated albuminuria or stage 1 or 2 CKD and severely increased albuminuria; a patient population at high CV risk that was excluded from or understudied in the FIGARO-DKD trial.
                  </p>
                </div>
              </div>
            </div>

            <div class="accordion-item">
              <h2 class="accordion-header" id="patients">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-7">
                  Patients
                </button>
              </h2>
              <div id="collapse-7" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    Patients (N=7437) who met the eligibility criteria at the end of a run-in period were randomly assigned in a 1:1 ratio to receive oral finerenone or placebo; patients with an eGFR at the screening visit of 25 and up to 60 mL/min/1.73 m<sup>2</sup> received an initial dose of 10 mg OD, and those with an eGFR of at least 60 mL/min/1.73 m<sup>2</sup> received an initial dose of 20 mg OD. From month 1 onward, the target dose of finerenone or placebo was 20 mg OD. Trial visits were conducted at month 1, month 4, and every 4 months thereafter until trial completion. During a run-in period, RAS inhibitor therapy was adjusted upward to a maximum tolerated dose.<sup>6</sup>
                  </p>
                </div>
              </div>
            </div>

            <div class="accordion-item">
              <h2 class="accordion-header" id="results">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-8">
                  Results
                </button>
              </h2>
              <div id="collapse-8" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    Mean age at baseline was 64.1 ± 9.7 in the finerenone group (N=3686) and 64.1 ± 10.0 in the placebo group (N=3666).<sup>6</sup>
                  </p>
                </div>
              </div>
            </div>
         
            <div class="accordion-item">
              <h2 class="accordion-header" id="efficacy outcomes">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-9">
                  Efficacy Outcomes
                </button>
              </h2>
              <div id="collapse-9" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">        
                    <li>
                      The primary composite outcome of incidence of CV-death, nonfatal MI, nonfatal stroke, or HHF was significantly lower in the finerenone group than in the placebo group (458/3686 patients [12.4%] vs. 519/3666 patients [14.2%]; HR, 0.87; 95% CI, 0.76 to 0.98; P = 0.03). This effect was consistent across prespecified subgroups.<sup>6</sup>
                    </li>
                    <li>
                      There was no significant between-group difference in the incidence of the first secondary composite outcome of kidney failure, a sustained decrease from baseline of at least 40% in eGFR, or renal-death which occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (HR, 0.87; 95% CI, 0.76 - 1.01).<sup>6</sup>
                    </li>
                  </ul>
                </div>
              </div>
            </div>

            <div class="accordion-item">
              <h2 class="accordion-header">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-10">
                  Safety Outcomes
                </button>
              </h2>
              <div id="collapse-10" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">               
                      <li>
                        Overall, 85.1% of patients in the finerenone and 85.5 % of patients in the placebo group experienced an AE. Of these, 31.4% and 33.2% were SAEs in the finerenone and placebo group, respectively.<sup>6</sup>
                      </li>
                      <li>
                        The incidence of hyperkalemia occurred in 10.8% and 5.3% of patients with finerenone and placebo, respectively. However, none of these AEs resulted in death; 1.2% and 0.4% led to permanent discontinuation of the trial regimen and 0.6% and 0.1% led to hospitalization in the finerenone and placebo groups, respectively.<sup>6</sup>
                      </li>
                      <li>
                        The incidence of hypokalemia occurred in 1.1% vs. 2.4% of patients, and gynecomastia occurred in 0.1% and 0.1% of patients with finerenone and placebo, respectively. AEs and SAEs of pneumonia occurred in 3.9% vs. 5.6% of the patients and in 2.0% vs. 3.1% of patients receiving finerenone and placebo, respectively.<sup>6</sup>
                      </li>
                      <li>
                        Finerenone treatment was associated with a greater increase of serum potassium levels from baseline than placebo. A between-group difference of 0.16 mmol/L was seen from month 1 and remained largely stable thereafter.<sup>6</sup>
                      </li>
                      <li>
                        Finerenone treatment had modest effects on blood pressure; the mean difference between finerenone and placebo in the change from baseline of systolic blood pressure was -3.5 mmHg at month 4 and -2.6 mmHg at month 24.<sup>6</sup>
                      </li>
                      <li>
                        The mean glycated hemoglobin levels and body weight values were similar in the two groups throughout the trial.<sup>6</sup>
                      </li>
                    </ul>
                  </div>
                </div>
              </div>   
             </div><br></div><br><br><br>
            </div>
        
      <div id="pooled_analysis-fidelity" class="tab-pane"  role="tabpanel">
        <div class="container-fluid">
          <h1>
            Pooled analysis - FIDELITY
          </h1>
          <div class="accordion">
            <div class="accordion-item">
              <h2 class="accordion-header">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-11">
                  Trial Design
                </button>
              </h2>
              <div id="collapse-11" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    In the pre-specified pooled analysis of FIDELIO-DKD and FIGARO-DKD <strong>(Agarwal et al 2021)<sup>7</sup></strong>, a total of 13 171 patients were randomized in a 1:1 ratio to receive finerenone 10mg or 20mg OD or placebo.
                  </p>
                </div>
              </div>
            </div>

            <div class="accordion-item">
              <h2 class="accordion-header">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-12">
                  Outcomes
                </button>
              </h2>
              <div id="collapse-12" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    The primary efficacy outcomes were a composite CV outcome of time to CV-death, non-fatal MI, non-fatal stroke, or HHF, and a composite kidney outcome of time to first onset of kidney failure, a sustained ≥57% decrease in eGFR from baseline over ≥4 weeks, or renal death. After a median follow-up of 3.0 years (interquartile range 2.3-3.8 years), the composite CV outcome occurred in 825 (12.7%) patients receiving finerenone and 939 (14.4%) receiving placebo (HR, 0.86; 95% CI, 0.78-0.95; P = 0.0018).<sup>7</sup>
                  </p>
                </div>
              </div>
            </div>

            <div class="accordion-item">
              <h2 class="accordion-header">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-13">
                  Efficacy Results
                </button>
              </h2>
              <div id="collapse-13" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <p class="collapse-text">
                    The composite kidney outcome occurred in 360 (5.5%) patients receiving finerenone and 465 (7.1%) receiving placebo (HR, 0.77; 95% CI, 0.67-0.88; P = 0.0002).<sup>7</sup>
                  </p>
                </div>
              </div>
            </div>
          
            <div class="accordion-item">
              <h2 class="accordion-header">
                <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#collapse-14">
                  Safety Results
                </button>
              </h2>
              <div id="collapse-14" class="accordion-collapse collapse">
                <div class="accordion-body">
                  <ul class="bullet-collapse">        
                    <li>
                      Overall safety outcomes were mostly similar between treatment arms. SAEs occurred in 31.6% of patients in the finerenone group and 33.7% of patients in the placebo group.<sup>7</sup>
                    </li>
                    <li>
                      Hyperkalaemia leading to permanent treatment discontinuation occurred more frequently in patients receiving finerenone (1.7%) than placebo (0.6%); however, no cases were fatal in either group and a small proportion led to permanent treatment discontinuation [1.7% (incidence rate 0.66 per 100 patient-years) and 0.6% (incidence rate 0.22 per 100 patient-years), respectively] or hospitalization (0.9% and 0.2%, respectively).<sup>7</sup>
                    </li>
                    <li>
                      Blood sodium decrease and hyponatremia and blood uric acid increase and hyperuricemia were reported as common (occurring in (≥1/100 to <1/10 patients) with finerenone use. Asymptomatic hyperuricemia was observed. In the FIGARO-DKD study, an increase from baseline in mean serum uric acid of up to 0.3 mg/dL was seen in the Kerendia group compared to placebo, which attenuated over time. No hyperuricemia related treatment discontinuations were reported.<sup>8</sup>
                    </li>
                  </ul>
                </div>
              </div>
            </div>   
          </div><br>
        </div><br><br><br>
      </div>

      <div id="references" class="tab-pane" role="tabpanel">
        <div class="container-fluid">
          <h1>
            References
          </h1>
          <ol style="margin-left: 30px; margin-right: 30px; margin-top: -20px; padding-right: 30px; padding-left: 30px; padding-bottom: 10px; padding-top: 10px; font-size: 20px;background-color: #f7f7f7;">
            <li>
              Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <em>Eur Heart J</em>. 2013;34(31):2453-2463
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/23713082/" target="_blank">PMID: 23713082</a>
            </li>
            <li>
              Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <em>JAMA</em>. 2015;314(9):884-894.
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/26325557/" target="_blank">PMID: 26325557</a>
            </li>
            <li>
              Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <em>Eur Heart J</em>. 2016;37(27):2105-2114.
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/27130705/" target="_blank">PMID: 27130705</a>
            </li>
            <li>
              Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. <em>N Engl J Med</em>. 2020;383(23):2219-2229.
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/33264825/" target="_blank">PMID: 33264825</a>
            </li>
            <li>
              <a href="https://www.nejm.org/doi/suppl/10.1056/NEJMoa2025845/suppl_file/nejmoa2025845_appendix.pdf" target="_blank">Supplement to</a>: Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. <em>N Engl J Med</em>. 2020;383:2219-29.
            </li>
            <li>
              Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <em>N Engl J Med</em>. 2021;385(24):2252-2263.
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/34449181/" target="_blank">PMID: 34449181</a>
            </li>
            <li>
              Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <em>Eur Heart J</em>. 2022;43(6):474-484.
              <br><a href="https://pubmed.ncbi.nlm.nih.gov/35023547/" target="_blank">PMID: 35023547</a>
            </li>
            <li>
              CCDS Finerenone (CKD T2D) Version 03 dated: 15 Dec 2021 [Accessed 03 Feb 2023] Data on file.
            </li>
          </ol>
        </div>
      </div>
      <br><br><br><br><br>
    </div>
        
    <footer class="fixed-bottom">
      <div class="container-fluid">
        <button type="button" class="btn btn-abbrev" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" data-bs-placement="right"title="Abbreviations" onclick="changeIcon(this)" data-bs-content="
          <strong>ACEI</strong> angiotensin converting enzyme inhibitor<br>
          <strong>AE</strong> adverse event<br>  
          <strong>ARB</strong> angiotensin-receptor blocker<br>
          <strong>ARR</strong> absolute risk reduction<br>
          <strong>CV</strong> cardiovascular<br> 
          <strong>CI</strong> confidence interval<br> 
          <strong>CKD</strong> chronic kidney disease<br>
          <strong>eGFR</strong> estimated glomerular filtration rate<br>
          <strong>HR</strong> hazard ratio<br>
          <strong>HF</strong> heart failure<br>
          <strong>HHF</strong> hospitalization for heart failure<br> 
          <strong>MI</strong> myocardial infarction<br> 
          <strong>NNT</strong> number needed to treat<br>
          <strong>OD</strong> once daily<br>
          <strong>RAS</strong> renin-angiotensin system<br>
          <strong>SAE</strong> serious adverse event<br>
          <strong>SBP</strong> systolic blood pressure<br>
          <strong>T2D</strong> type 2 diabetes<br>
          <strong>TEAE</strong> treatment-emergent adverse event<br> 
          <strong>UACR</strong> urinary albumin-to-creatinine ratio<br>">
        <i id ="fa" class="fas fa-list"></i>
        </button>

        <button type="button" class="btn btn-ref" data-bs-toggle="popover" data-bs-container="body" data-bs-html="true" data-bs-placement="right" title="References" onclick="changeIcon(this)" data-bs-content="
          <ol>
            <li>
              Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <em>Eur Heart J</em>. 2013;34(31):2453-2463.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/23713082' target='_blank'>PMID: 23713082</a>
            </li>
            <li>
              Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <em>JAMA</em>. 2015;314(9):884-894.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/26325557' target='_blank'>PMID: 26325557</a>
            </li>
            <li>
              Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <em>Eur Heart J</em>. 2016;37(27):2105-2114.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/27130705/' target='_blank'>PMID: 27130705</a>
            </li>
            <li>
              Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. <em>N Engl J Med</em>. 2020;383(23):2219-2229.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/33264825/' target='_blank'>PMID: 33264825</a>
            </li>
            <li>
              <a href='https://www.nejm.org/doi/suppl/10.1056/NEJMoa2025845/suppl_file/nejmoa2025845_appendix.pdf' target='_blank'>Supplement to</a>: Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219-29.
            </li>
            <li>
              Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <em>N Engl J Med</em>. 2021;385(24):2252-2263.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/34449181/' target='_blank'>PMID: 34449181</a>
            </li>
            <li>
              Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <em>Eur Heart J</em>. 2022;43(6):474-484.
              <br><a href='https://pubmed.ncbi.nlm.nih.gov/35023547/' target='_blank'>PMID: 35023547</a>
            </li>
            <li>
              CCDS Finerenone (CKD T2D) Version 03 dated: 15 Dec 2021 [Accessed 03 Feb 2023] Data on file.
            </li>
           </ol>">
          <i id="fa" class="fas fa-scroll"></i>
        </button>
      </div>
      <a href="#" id="scroll" style="display: none;"><span></span></a>
    </footer>
  
  <script>  
    const popoverTriggerList = document.querySelectorAll('[data-bs-toggle="popover"]')
    const popoverList = [...popoverTriggerList].map(popoverTriggerEl => new bootstrap.Popover(popoverTriggerEl))
  </script>

</body>
</html>